Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (26)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Gudas, J. M.
Right arrow Articles by Cowan, K. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gudas, J. M.
Right arrow Articles by Cowan, K. H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 Oxford University Press

research-article

CANCER BIOLOGY: Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein

Jean M. Gudas 2, Hoang Nguyen 1 {dagger}, Tao Li 1 {dagger}, Lisa Sadzewicz 1, Robert Robey, Katja Wosikowksi and Kenneth H. Cowan

Medicine Branch, Division of Cancer Treatment, Medical Breast Cancer Section, National Cancer Institute Building 10, Room I2N226, Bethesda, MD 20892
1Oncor Med 205 Perry Parkway, Gaithersburg. MD 20877, USA

2To whom correspondence should be addressed at: Amgen Inc., Mail Stop 14–2-C, Thousand Oaks, CA 91320, USA

Abnormalities in the p53 tumor suppressor gene have been shown to affect cellular processes related to cell cycle control and gene amplification. In this study we compare the status and function of wild-type p53 in MCF-7 breast cancer cells with sublines selected for resistance to chemo-therapeutic agents having different mechanisms of action. Sublines that were resistant to melphalan, pyrazafurin, mitoxantrone, etoposide and PALA all retained expression of wild-type p53. Methotrexate-resistant MCF-7 cells were unusual heterozygotes that expressed a wild-type and dominant, in-frame p53 deletion mutant and the doxorubicin-resistant cells expressed only mutant p53. Analysis of the Gl checkpoint after treatment with ionizing radiation revealed that the pyrazafurin-, melphalan- and mitoxan-trone-resistant cells arrested strongly in Gl. The etoposide-and PALA-resistant cells had an intermediate Gl arrest phenotype and the methotrexate- and doxorubicin-resistant cells had a minimal Gl arrest phenotype. mRNA and protein analyses of downstream effector genes, including p21CIP1A/Waf1, mdm2, Gadd 45 and the retinoblastoma protein, did not entirely differentiate sublines having a strong versus intermediate Gl arrest phenotype. Neither the p53 status nor the strength of the Gl arrest could be correlated with cell survival after ionizing radiation. When drug-sensitive MCF-7 cells were treated with the same chemotherapeutic agents, p53 and p21CIPI/Waf1 levels increased between 2-and 14-fold. Together these data suggest that other cellular factors likely play a role in overcoming the inhibitory effects of ionizing radiation on p53 in drug-resistant breast cancer cells.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Nutr.Home page
H. Mo and C. E. Elson
Apoptosis and Cell-Cycle Arrest in Human and Murine Tumor Cells Are Initiated by Isoprenoids
J. Nutr., April 1, 1999; 129(4): 804 - 813.
[Abstract] [Full Text]


Home page
J. Immunol.Home page
R. J. Rayanade, M. I. Ndubuisi, J. D. Etlinger, and P. B. Sehgal
Regulation of IL-6 Signaling by p53: STAT3- and STAT5-Masking in p53-Val135-Containing Human Hepatoma Hep3B Cell Lines
J. Immunol., July 1, 1998; 161(1): 325 - 334.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.